ArriVent BioPharma, Inc. (AVBP)
Market Cap | 616.62M |
Revenue (ttm) | n/a |
Net Income (ttm) | -74.58M |
Shares Out | 33.49M |
EPS (ttm) | -2.23 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 44,132 |
Open | 18.18 |
Previous Close | 18.15 |
Day's Range | 17.78 - 18.44 |
52-Week Range | 14.35 - 25.95 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 29.25 (+58.88%) |
Earnings Date | Aug 2, 2024 |
About AVBP
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal grow... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AVBP stock is "Strong Buy." The 12-month stock price forecast is $29.25, which is an increase of 58.88% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/u/n/press3-2463199.jpg)
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
Collaboration will leverage Alphamab's antibody drug conjugate (“ADC”) research and discovery platform and ArriVent's global development and commercialization expertise
![](https://cdn.snapi.dev/images/v1/q/o/press12-2435996.jpg)
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, t...
![](https://cdn.snapi.dev/images/v1/g/g/press19-2417844.jpg)
ArriVent BioPharma Reports First Quarter 2024 Financial Results
NEWTOWN SQUARE, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of in...
![](https://cdn.snapi.dev/images/v1/o/s/press19-2384094.jpg)
ArriVent Appoints Kristine Peterson to its Board of Directors
NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics,...
![](https://cdn.snapi.dev/images/v1/d/z/press16-2347622.jpg)
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
BEIJING, China--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study...
![](https://cdn.snapi.dev/images/v1/w/e/press3-2347165.jpg)
ArriVent BioPharma Reports Full Year 2023 Financial Results
NEWTOWN SQUARE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of ...
![](https://stockanalysis.com/img/news/press-release-1.jpg)
ArriVent Announces Pricing of Upsized Initial Public Offering
ArriVent BioPharma, Inc. (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics...
![](https://stockanalysis.com/img/news/nasdaq1.jpg)
Cancer biotech ArriVent Biopharma files for a $100 million IPO
ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
![](https://stockanalysis.com/img/news/ipo13.jpg)
ArriVent BioPharma IPO Registration Document (S-1)
ArriVent BioPharma has filed to go public with an IPO on the NASDAQ.